Keith J. Kendall

Overview

Keith J. Kendall received an average of $3M in total compensation, including $523K in salary, at Aquestive Therapeutics from 2018 to 2021.

Source: SEC filings on April 29, 2022, May 5, 2021, and April 29, 2020.

Related executives

We found three more executives who work or worked at Aquestive Therapeutics.

Daniel Barber

Aquestive Therapeutics

Chief Operating Officer

A Toth

Aquestive Therapeutics

Chief Financial Officer

John Maxwell

Aquestive Therapeutics

Chief Financial Officer

News

You may also like